Table 1.
Clinico-pathological data and distribution of scores in the entire cohort of patients
| |
E-cadherin |
Nuclear β-catenin |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Factors | N (%) 98 (100) | Absent | Low | Mode-rate | High | Absent | Low | Mode-rate | High |
| Sex |
|
|
|
|
|
|
|
|
|
| M |
72 (73%) |
1 (1%) |
2 (3%) |
13 (18%) |
56 (78%) |
30 (42%) |
26 (36%) |
12 (17%) |
4 (6%) |
| F |
26 (27%) |
1 (4%) |
0 (0%) |
5 (19%) |
20 (77%) |
9 (35%) |
9 (35%) |
6 (23%) |
2 (8%) |
| Age |
|
|
|
|
|
|
|
|
|
| </= 50 |
48 (49%) |
2 (2%) |
1 (1%) |
15 (18%) |
66 (77%) |
33 (39%) |
31 (37%) |
15 (18%) |
5 (6%) |
| >50 |
50 (51%) |
0 (0%) |
1 (7%) |
3 (21%) |
10 (72%) |
6 (43%) |
4 (29%) |
3 (21%) |
1 (7%) |
| Anal margin |
|
|
|
|
|
|
|
|
|
| <= 5 cm |
84 (86%) |
1 (2%) |
1 (2%) |
7 (15%) |
39 (81%) |
21 (44%) |
17 (35%) |
7 (15%) |
3 (6%) |
| >5 cm |
4 (14%) |
1 (2%) |
1 (2%) |
11 (22%) |
37 (72%) |
18 (36%) |
18 (36%) |
11 (22%) |
3 (6%) |
| T stage |
|
|
|
|
|
|
|
|
|
| T2-3 |
80 (82%) |
2 (3%) |
2 (3%) |
15 (19%) |
61 (85%) |
29 (36%) |
30 (37%) |
15 (19%) |
6 (8%) |
| T4 |
18 (18%) |
0 (0%) |
0 (0%) |
3 (17%) |
15 (83%) |
10 (56%) |
5 (28%) |
3 (17%) |
0 (0%) |
| N stage |
|
|
|
|
|
|
|
|
|
| N- |
43 (44%) |
0 (0%) |
1 (2%) |
7 (13%) |
44 (85%) |
21 (40%) |
16 (31%) |
12 (23%) |
3 (6%) |
| N+ |
55 (56%) |
2 (4%) |
1 (2%) |
11 (24%) |
32 (70%) |
18 (39%) |
19 (41%) |
6 (13%) |
3 (7%) |
| TGR* |
|
|
|
|
|
|
|
|
|
| TGR 1 |
17 (17%) |
0 (0%) |
1 (6%) |
3 (18%) |
13 (76%) |
5 (29%) |
9 (53%) |
2 (12%) |
1 (6%) |
| TGR 2 |
27 (28%) |
1 (4%) |
0 (0%) |
3 (11%) |
23 (85%) |
7 (26%) |
11 (41%) |
7 (26%) |
2 (7%) |
| TGR 3 |
23 (24%) |
1 (4%) |
1 (4%) |
2 (9%) |
19 (83%) |
11 (48%) |
6 (26%) |
4 (17%) |
2 (9%) |
| TGR 4 |
26 (26%) |
0 (0%) |
0 (0%) |
8 (31%) |
18 (69%) |
14 (54%) |
7 (27%) |
4 (15%) |
1 (4%) |
| TGR 5 |
5 (5%) |
0 (0%) |
0 (0%) |
2 (40%) |
3 (60%) |
8 (40%) |
2 (40%) |
1 (20%) |
0 (0%) |
| pN †† |
|
|
|
|
|
|
|
|
|
| pN- |
70 (71%) |
2 (3%) |
1 (1%) |
13 (19%) |
54 (77%) |
27 (39%) |
26 (37%) |
12 (17%) |
5 (7%) |
| pN+ | 28 (29%) | 0 (0%) | 1 (4%) | 5 (18%) | 22 (78%) | 12 (43%) | 9 (32%) | 6 (21%) | 1 (4%) |
*TGR: Tumor grade regression. †† pN: pathological lymphatic metastases.